Lupus Foundation of America25d
New Study Finds Anifrolumab In Addition to Standard of Care Treatment is Effective at Reducing Organ Damage Accumulation
A recent study evaluated the effectiveness of anifrolumab (Saphnelo®) combined with standard of care (SOC) treatments compared to SOC treatment alone in preventing organ damage. Results showed that ...
Monthly Prescribing Reference25d
Anifrolumab Tied to Less Organ Damage for Patients With Lupus
The likelihood of experiencing an increase in Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index within 208 weeks was lower for patients in the ...
Hosted on MSN26d
Anifrolumab Tied to Less Organ Damage for Patients With Lupus
THURSDAY, Feb. 20, 2025 (HealthDay News) -- For patients with moderately to severely active systemic lupus erythematosus (SLE), anifrolumab is associated with less organ damage after 208 weeks ...
healthday26d
Anifrolumab Tied to Less Organ Damage for Patients With Lupus
THURSDAY, Feb. 20, 2025 (HealthDay News) -- For patients with moderately to severely active systemic lupus erythematosus (SLE), anifrolumab is associated with less organ damage after 208 weeks ...
healthday27d
Drug Can Stave Off Organ Damage From Lupus
But a newer lupus drug appears to protect patients from much of this organ damage, a new study suggests. Anifrolumab (brand name Saphnelo) reduced the risk of long-term organ damage progression by ...
Medical Xpress27d
Drug can stave off organ damage from lupus, research reveals
Anifrolumab (brand name Saphnelo) reduced the risk of long-term organ damage progression by about 60% in patients with moderately to severely active lupus, researchers reported in a new study ...
Tyler Morning Telegraph27d
Drug Can Stave Off Organ Damage From Lupus
Anifrolumab (Saphnelo) lowered the risk of long-term organ damage progression by about 60% The drug received federal approval in 2021 WEDNESDAY, Feb. 19, 2025 (HealthDay News) -- Lupus can do ...
Pharmaceutical Technology1mon
Royalty Pharma pays $250m for rights to Biogen’s lupus drug
These include GSK’s Benlysta (belimumab) and AstraZeneca’s Saphnelo (anifrolumab). The market for CLE, however, has seen even less innovation. CLE is a form of lupus that primarily affects the skin, ...
National Institute for Health and Care Excellence1mon
Published guidance, NICE advice and quality standards
Guidance on the use of capecitabine and tegafur with uracil for metastatic colorectal cancer TA61 27 May 2003 27 May 2003 Guidance on the use of drugs for early thrombolysis in the treatment of acute ...
clinicaltrialsarena1mon
AnaptysBio achieves ‘highest ever’ results in Phase II rheumatoid arthritis trial
The study achieved its primary endpoint in eliciting a mean change from baseline using the 28-Joint Disease Activity Score. credit: Shuttertstock / jittawit21. AnaptysBio’s Phase IIb trial of its ...
Consultancy4mon
L.E.K. Consulting
Since 1983, our worldwide practice — spanning the Americas, Asia-Pacific and Europe — has guided leaders across all industries, from global corporations to emerging entrepreneurial businesses and ...